Psychiatry

Your daily dose of the clinical news you may have missed.

The FDA advisory committee overwhelmingly voted against Otsuka's PTSD treatment, citing insufficient evidence from clinical trials for approval.

FDA's Psychopharmacologic Drugs Advisory Committee will evaluate the novel brexpiprazole/sertraline combination, weighing efficacy against existing therapies amid mixed trial results.

Monu Khanna, MD, discusses the benefits of behavioral strategies, including yoga, breathwork, and dancing, in reducing cardiovascular disease risk in patients with obesity.

Maternal depression significantly disrupts parenting behaviors, impacting child development and emotional bonding, according to an updated international literature review.

TSND-201, a rapid-acting neuroplastogen, demonstrated statistically significant symptom improvement by day 10, which was durable throughout the study until Day 64.

A single dose of BPL-003 was associated with improved MADRS scores as early as day 2 that were durable through week 8; phase 3 planning is anticipated.

Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.

Your daily dose of the clinical news you may have missed.

ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.

The novel rapid-acting psychedelic agent produced antidepressant effects within 24 hours after the first infusion, with a -18.5 point change in MADRS from baseline.

Youth depression is often diagnosed during crisis events, underscoring the need for primary care education and enhanced collaborative care resources.

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

New data from UNITE study suggest fremanezumab was effective in alleviating migraine and comorbid MDD in patients with both conditions.

Researchers will study brain activity and daily function in patients with BPD using wearable EEG and digital cognitive tools in a first-of-its-kind real-world study.

Approximately 40% of adults with chronic pain have comorbid anxiety and/or depression, underscoring the importance of routine screening in this population.

Your daily dose of the clinical news you may have missed.

Suicide prevention falls squarely in the purview of primary care practitioners, says family physician Teresa Lovins, MD. She reviews an intervention with remarkable results.

Your daily dose of the clinical news you may have missed.

ACP 2025: Matthew Press, MD, shares actionable steps for primary care physicians to adopt a collaborative care model, including how to start small and partner with other practices.

ACP 2025: Dr Press discusses how the Penn Integrated Care model equips primary care physicians to manage mental health conditions more effectively while reducing burnout.

ACP 2025: Discover how the collaborative care model supports mental health in primary care through team-based care, symptom tracking, and psychiatric consultation—boosting outcomes and reducing burden on clinicians.

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.

In the pediatric population aged 0 to 19 years, exposure to fentanyl was through intentional use by two-thirds, investigators found.

More than one-third of study participants with TRD had failed to get relief from 4 or more antidepressants, calling treatment experiences a "trial and error" process.

Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.

Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.

The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.